Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Immune checkpoint inhibitors (ICIs), though revolutionary in cancer treatment ... In addition, 8 subgroups were assessed: (1) patients with melanoma, (2) patients without a history of cardiovascular ...

1Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate ...

Patients with melanoma and colorectal cancer ... currently investigating the possibility of BRAF degraders since BRAF/MEK inhibitor combinations are being utilized to treat a variety of cancer ...

there were no approved biomarker-driven therapies specifically indicated for people with previously untreated BRAF V600E -mutant mCRC. Braftovi is an oral small molecule kinase inhibitor that targets ...

This BRAF/CRAF inhibitor is being evaluated in a Phase 3 study called SEACRAFT-2 as part of a combination therapy with Mikinist (trametinib) from Novartis to treat NRASm melanoma. The primary ...

all four class 1 MAP2K1-mutant tumors that experienced a response to treatment were in the context of coexisting BRAF V600E mutations treated with BRAF inhibitors. Class 2 MAP2K1 mutants fall between ...

We have been fortunate that inhibitors targeting the pathways affected by these mutations already exist. Building on top of the work of other research teams—science and research is like being a ...

The dual primary endpoints are ORR, which was met at the time of analysis, and PFS as assessed by BICR. OS is a key secondary endpoint. BRAFTOVI is an oral small molecule kinase inhibitor that targets ...

Systematic literature review (SLR) of prognostic factors (PFs) in locally advanced rectal cancer (LARC) and mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer (RC).